Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz1, R Hehlmann2, A Quintás-Cardama3, J Mercer1 and J Cortes3
You are here
Online Broadcast Event: CML: The Patient's Journey
Date:
Thursday, November 12, 2015 - 7:30pm
Event type:
Musculoskeletal Pain - TKI Withdrawal Syndrome?
Rousselot et al1 recently reported on the According to Stop Imatinib (A-STIM) study evaluating the persistence of major molecular response (MMR) in patients with chronic-phase chronic myeloid leukemia (CP CML) who had discontinued imatinib after prolonged deep molecular remission. They found that 61% of the patients were still in MMR and were treatment free after 36 months, whereas those who lost MMR and restarted tyrosine kinase inhibitor (TKI) therapy all regained MMR. They concluded that loss of MMR is a safe criterion for restarting therapy after TKI discontinuation.
- Read more about Musculoskeletal Pain - TKI Withdrawal Syndrome?
- Log in or register to post comments
- Email this page
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib
Merrill J Egorin,1,2,3 Dhvani D Shah,1 Susan M Christner,1 Mara A Yerk,4 Kristin A Komazec,4 Leonard R Appleman,2 Robert L Redner,2 Brian M Miller,5 and Jan H Beumer1,6
Abstract
AIMS
Cancer Drugs Fund: CML Support is a signatory to a letter to The Times on November 4th, the day bosutinib is delisted
CDF Issues:
Government responds to Cancer Drugs Fund Petition on Blood Cancers
CDF Issues:
Government responds to Cancer Drugs Fund Petition on Blood Cancers
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists
Whether cancer is maintained by a small number of stem cells or is composed of proliferating cells with approximate phenotypic equivalency is a central question in cancer biology1. In the stem cell hypothesis, relapse after treatment may occur by failure to eradicate cancer stem cells. Chronic myeloid leukaemia (CML) is quintessential to this hypothesis. CML is a myeloproliferative disorder that results from dysregulated tyrosine kinase activity of the fusion oncoprotein BCR–ABL.
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation
Nature:
International Weekly Journal of Science
DASISION
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for CML in chronic phase
BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during first-line treatment with dasatinib and nilotinib, despite increased use because of higher response rates compared with imatinib.
Dasatinib, Imatinib, Associated With Differing Mutation Patterns in CML
July 10, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma
Patients with chronic myeloid leukemia (CML) undergoing treatment with dasatinib had a narrower spectrum of mutations in BCR-ABL1 compared to those treated with imatinib, according to a new study, a finding which could aid in selection of second-line treatments. -
July 10, 2015 | Chronic Myeloid Leukemia, Hematologic Malignancies, Leukemia & Lymphoma
Patients with chronic myeloid leukemia (CML) undergoing treatment with dasatinib had a narrower spectrum of mutations in BCR-ABL1 compared to those treated with imatinib, according to a new study, a finding which could aid in selection of second-line treatments. -